Clozapine toxicity: A discussion of pharmacokinetic factors

Asian Journal of Psychiatry

Volumn 1, Issue 2, 2008, Pages 47-49

  Shad, Mujeeb U ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Clozapine; Factors; Pharmacokinetic; Toxicity

Indexed keywords

CLOZAPINE; CYTOCHROME P450 1A2; LITHIUM; NORCLOZAPINE; PROPRANOLOL; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; CONFUSION; CONSCIOUSNESS DISORDER; DISORIENTATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; GENOTYPE; HUMAN; KIDNEY FUNCTION TEST; MALE; PETIT MAL; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SYMPTOM; TREATMENT RESPONSE;

EID: 56849107363     PISSN: 18762018     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajp.2008.09.001     Document Type: Article

References (12)

1. Bertilsson L., Carrillo J., Dahl M.L., Llerna A., Alm C., Bondesson U., et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Am. J. Psychiatry 38 (1994) 471-473
2. Carrillo J.A., Herraiz A.G., Ramos S.I., and Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J. Clin. Psychopharmacol. 18 (1998) 311-316
3. CLOZARIL (Clozapine) Novartis, 2001a. Physicians' Desk Reference. 55, pp. 2042-2044.
4. CLOZARIL (Clozapine) Novartis, 2001b. AHFS Drug Information, 27, pp. 1739-1742.
5. Dequardo J., and Roberts M. Elevated clozapine levels after fluvoxamine initiation (Letter). Am. J. Psychiatry 153 (1996) 840-841
6. Hiemke C., Weigmann H., Hartter S., Dahmen N., Wetzel H., and Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol. 14 (1994) 279-281
7. Johnson J.A., Herring V.L., Wolfe M.S., and Relling M.V. CYP1A2 and CYP2D6 4-hydroxylates propranolol and both reactions exhibit racial differences. J. Pharmacol. Exp. Ther. 294 (2000) 1099-1105
8. Khan A.Y., and Preskorn S.H. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J. Psychiatr. Pract. 11 5 (2005) 289-301
9. Naranjo C.A., Busto U., Sellers P., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30 (1981) 239-245
10. Perry P.J., Miller D.D., Arndt S.V., and Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychiatry 148 (1991) 231-235
11. Pirmohamed M., Williams D., Madden S., Templeton E., and Park K.B. Metabolism and bioactivation of Clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272 (1995) 984-990
12. Weigmann H., Muller H., and Dahmen N. Interactions of fluvoxamine with the metabolism of clozapine (Letter). Am. J. Psychiatry 26 (1993) 209